Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Single Agent Chemotherapy in NSCLC with ECOG PS 2
NCT04297605Phase 1Recruiting
- Sponsor
- University of Rochester
- Start
- May 2020
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Rochester. Primary endpoint: Adverse Events at 18 months. Started May 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04297605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297605.